SyntekaBio

SyntekaBio FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of SyntekaBio (226330.KQ) as of Nov 19, 2026 is 61.76 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 226.33 % — a change of -72.71% (lower).

FCF Conversion

61.76 %

YoY

-72.71%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of SyntekaBio is 2025 61.76 % . FCF Conversion Rate (FCF/EBITDA) of SyntekaBio was 2024 226.33 % . It decreases by -72.71% lower compared to the previous year.

The SyntekaBio FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-80.53 KRW
Jan 1, 2019
17.94 KRW
Jan 1, 2020
84.11 KRW
Jan 1, 2021
91.33 KRW
Jan 1, 2022
383.18 KRW
Jan 1, 2023
153.61 KRW
Jan 1, 2024
226.33 KRW
Jan 1, 2025
61.76 KRW
The SyntekaBio FCF Conversion history
YEARFCF ConversionYoY
61.76 %-72.71%
226.33 %+47.34%
153.61 %-59.91%
383.18 %+319.54%
91.33 %+8.59%
84.11 %+368.71%
17.94 %-122.28%
-80.53 %-282.27%
44.18 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SyntekaBio Stock analysis

What does SyntekaBio do? SyntekaBio Inc. provides bioinformatics solutions through AI-driven software and services. The company develops and sells PMAP, a personal algorithm dielectric map platform using artificial intelligence, and offers clinical trial modeling and genome analysis services via big data. These services diagnose genetic diseases, select biomarker treatments, and predict disease risk. SyntekaBio also develops AI drug development technology and provides research services for candidate substances of immuno-cancer drugs. The primary customers for SyntekaBio's products include healthcare providers, research institutions, and pharmaceutical companies. Healthcare providers use the diagnostic and predictive services for patient care, while research institutions and pharmaceutical firms utilize the genome analysis and drug development technologies. The company's AI-driven tools are tailored to meet the needs of these segments, focusing on precision medicine and oncology applications. SyntekaBio's revenue streams come from software sales, service contracts for clinical trial modeling and genome analysis, and research services for immuno-cancer drug candidates. The company's AI drug development technology is a key offering, targeting pharmaceutical companies seeking to accelerate drug discovery and development processes. The firm's focus on AI and big data analytics positions it as a provider of specialized solutions in the bioinformatics sector. SyntekaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SyntekaBio stock

FCF Conversion Rate (FCF/EBITDA) of SyntekaBio is 61.76 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of SyntekaBio changed from 226.33 % to 61.76 %, representing a -72.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) SyntekaBio since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s SyntekaBio with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — SyntekaBio

All Key Metrics — SyntekaBio